Hematology and Transfusion Medicine Center, University of Campinas/Hemocentro UNICAMP, Campinas, São Paulo, Brazil.
Stem Cell Res Ther. 2018 Feb 12;9(1):34. doi: 10.1186/s13287-017-0765-1.
CXCR4 was the first receptor identified for CXCL12, but a second receptor, CXCR7, has also been described and its function in hematopoietic cells remains unknown. By inhibition of CXCR4 and/or CXCR7, we showed that CXCR7 participates in normal CD34 and U937 cell migration and prevents downregulation of CXCR4 by CXCL12 stimulation. In addition, CXCR7 contributes to homing of acute myeloid leukemia and normal progenitor cells to the bone marrow and spleen of NOD/SCID mice. In summary, this study shows an essential role of CXCR7, together with CXCR4, in the control of normal and malignant hematopoietic cell migration and homing induced by CXCL12.
趋化因子受体 4（CXCR4）是第一个被鉴定出来的趋化因子配体 12（CXCL12）的受体，但也已经描述了第二个受体，即趋化因子受体 7（CXCR7），其在造血细胞中的功能仍然未知。通过抑制 CXCR4 和/或 CXCR7，我们发现 CXCR7 参与正常 CD34 和 U937 细胞的迁移，并防止 CXCL12 刺激导致 CXCR4 的下调。此外，CXCR7 有助于急性髓系白血病和正常祖细胞归巢到 NOD/SCID 小鼠的骨髓和脾脏。总之，这项研究表明，CXCR7 与 CXCR4 一起，在控制由 CXCL12 诱导的正常和恶性造血细胞迁移和归巢中发挥重要作用。
